An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency.
Saved in:
| Title: | An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency. |
|---|---|
| Authors: | Hope, Kevin A.1 (AUTHOR), Berman, Alexys R.1 (AUTHOR), Peterson, Randall T.2 (AUTHOR), Chow, Clement Y.1 (AUTHOR) cchow@genetics.utah.edu |
| Source: | PLoS Genetics. 6/2/2022, Vol. 18 Issue 6, p1-20. 20p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 15537390 |
|---|---|
| DOI: | 10.1371/journal.pgen.1010228 |
